This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ubiquitin Specific Protease (USP) Program

Roche Holding AG

Drug Names(s): USP Program

Description: The Ubiquitin Specific Protease (USP) Program is a discovery and development program to identify small molecule inhibitors of a ubiquitin specific protease (USP) target.

Deal Structure: Genentech and Almac Discovery
In June 2015, Almac Discovery announced a Research and Licensing agreement with Genentech, a member of the Roche Group, to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target. Under the terms of the agreement, Almac Discovery will receive an upfront payment of $14.5 million. Almac Discovery will be eligible to receive up to $349 million in payments based on achievement of certain predetermined milestones as well as escalating tiered royalties on potential commercial sales of multiple products to the target by Genentech. Almac Discoverys novel, potent and selective small molecule inhibitors will be the starting point for a two-year joint research program funded by Genentech. Genentech will be responsible for all preclinical and clinical development and commercialization of products arising from the collaboration.

Partners: Almac Group

Ubiquitin Specific Protease (USP) Program News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug